May 07, 2020
Oculis Announces Presentation of Results From Its Phase 2 (SKYGGN) Trial of OCS-01 for Inflammation and Pain Following Cataract Surgery at Upcoming ASCRS Annual Meeting 2020
May 05, 2020
KYPROLIS® (carfilzomib) Patents Upheld Against Generic Manufacturer
Mar 23, 2020
The Lancet Haematology Publishes Results From Oncopeptides' Multicenter, International Phase 1/2 Study (O-12-M1)
Mar 02, 2020
Eyevance Pharmaceuticals launches TOBRADEX® ST in the United States
Mar 02, 2020
Eyevance Pharmaceuticals launches TOBRADEX® ST in the United States
Feb 03, 2020
GSK announces European Medicines Agency (EMA) accepted marketing authorisation application for belantamab mafodotin for the treatment of relapsed or refractory multiple myeloma
Jul 08, 2019
EyePoint Pharmaceuticals, Inc. - U.S. Commercialization of DEXYCU® (dexamethasone intraocular suspension) 9%
Jun 03, 2019
New Data from Oncopeptides Phase 1/2 O-12-M1 Trial Evaluating Melflufen in RRMM Presented at 2019 ASCO Annual Meeting
May 22, 2019
NTC Grants Further License and Distribution Rights to Santen for Its Fixed Combination Dexamethasone With Levofloxacin in South East Asia
Dec 02, 2018
Oncopeptides Presents First Interim Data From the Ongoing Combination Trial ANCHOR With Melflufen at the 60th American Society of Hematology Meeting
Aug 27, 2018
Amgen Submits Supplemental New Drug Application For KYPROLIS® (carfilzomib) Once-Weekly 70 mg/m2 In Combination With Dexamethasone
Jun 05, 2018
PharmaMar Presents in Oral Session at ASCO: The ADMYRE Study's Adjusted Overall Survival With Plitidepsin
Jan 17, 2018
FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label
Dec 11, 2017
New Data for DARZALEX® (daratumumab) Presented at ASH 2017 Showed Feasibility of Subcutaneous Use and Promise of DARZALEX as a Treatment for Smoldering Multiple Myeloma
Dec 11, 2017
PharmaMar Presents Positive Results of the Pivotal Phase III Trial with Plitidepsin in Multiple Myeloma During the ASH Meeting
Oct 30, 2017
Allergan Receives Approval for Ozurdex® (Dexamethasone Intravitreal Implant 0.7 mg) in China for the Treatment of Retinal Vein Occlusion (RVO)
Aug 23, 2017
Overall Survival Analysis From KYPROLIS® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology